Results 261 to 270 of about 51,765 (315)
Some of the next articles are maybe not open access.
Interaction of Clopidogrel and Omeprazole
New England Journal of Medicine, 2010To the Editor: The label for clopidogrel warns physicians to “avoid concomitant use of . . . strong or moderate CYP2C19 inhibitors.” Such inhibitors (e.g., omeprazole) decrease the formation of the active metabolite of clopidogrel, the source of its antiplatelet effects.
Robert Temple, Mary Ross Southworth
openaire +2 more sources
Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension
American Journal of Health-System Pharmacy, 2001The pharmacokinetics of omeprazole delayed-release capsules and a simplified omeprazole suspension (SOS) were studied. Seven healthy volunteers randomly received either one 20-mg omeprazole delayed-release capsule or SOS (omeprazole 20 mg in 10 mL) for seven days before being crossed over to the opposite treatment for seven more days after a two-week ...
RA Quercia +4 more
openaire +3 more sources
Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse.
Journal of Veterinary Pharmacology and Therapeutics, 2015The objectives were to document the pharmacokinetics of intravenous, enteric-coated oral and plain oral omeprazole in fasted horses and to investigate the impact of feeding on the bioavailability of an enteric-coated omeprazole.
B. Sykes +3 more
semanticscholar +1 more source
Erythrodermia induced by omeprazole
Int. Journal of Clinical Pharmacology and Therapeutics, 2001To report a case of erythrodermia that appears to be related to the intake of omeprazole (OMP) for treatment of gastroesophageal reflux disease.We describe a case of erythrodermia associated with OMP therapy in a 58-year-old white woman with no predisposing factors.
Navarro-Blasco F +4 more
openaire +3 more sources
The Clinical Safety of Omeprazole
Digestion, 1989This review comprises data from more than 19,000 individuals who have taken part in clinical studies of omeprazole. Isolated, non-specific adverse events which might be attributable to omeprazole have included nausea, dizziness, headache and diarrhoea. These events have been generally mild and transient and have not usually required either a reduction ...
openaire +4 more sources
Pediatric Emergency Care, 2005
Omeprazole; the first proton pump inhibitor (PPI) showing an effective acid inhibitory ability, provides the satisfactory therapy either in gastro-esophageal reflux symptom relief or in healing of erosive esophagitis. It's also effective in peptic ulcer disease. Up to date, omeprazole efficacy and safety are well established in many trials.
Wael El-Matary, Mark Dalzell
openaire +2 more sources
Omeprazole; the first proton pump inhibitor (PPI) showing an effective acid inhibitory ability, provides the satisfactory therapy either in gastro-esophageal reflux symptom relief or in healing of erosive esophagitis. It's also effective in peptic ulcer disease. Up to date, omeprazole efficacy and safety are well established in many trials.
Wael El-Matary, Mark Dalzell
openaire +2 more sources
2010
Publisher Summary Omeprazole is a proton pump inhibitor that inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase, the “proton pump” of the gastric parietal cell. The drug is used in conditions, where the inhibition of gastric acid secretion may be beneficial, including aspiration
openaire +3 more sources
Publisher Summary Omeprazole is a proton pump inhibitor that inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase, the “proton pump” of the gastric parietal cell. The drug is used in conditions, where the inhibition of gastric acid secretion may be beneficial, including aspiration
openaire +3 more sources
Scandinavian Journal of Gastroenterology, 1995
Omeprazole causes irreversible inhibition of the hydrogen/potassium adenosine triphosphatase enzyme, leading to a marked reduction in both acid secretion and volume of gastric juice. Reported side-effects include nausea, vomiting, diarrhoea, constipation, and headache.
M. W. Whitehead +5 more
openaire +3 more sources
Omeprazole causes irreversible inhibition of the hydrogen/potassium adenosine triphosphatase enzyme, leading to a marked reduction in both acid secretion and volume of gastric juice. Reported side-effects include nausea, vomiting, diarrhoea, constipation, and headache.
M. W. Whitehead +5 more
openaire +3 more sources
, 2014
Summary Reasons for performing the study A recent study suggested that the duration of acid suppression achieved with once-daily administration of omeprazole is as short as 12 h and that administration of omeprazole prior to exercise may be superior ...
B. Sykes, K. M. Sykes, G. Hallowell
semanticscholar +1 more source
Summary Reasons for performing the study A recent study suggested that the duration of acid suppression achieved with once-daily administration of omeprazole is as short as 12 h and that administration of omeprazole prior to exercise may be superior ...
B. Sykes, K. M. Sykes, G. Hallowell
semanticscholar +1 more source